Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Genetic engineering deployed to insert gene for human insulin into a bacterium, thus harnessing the substance for widespread ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

If Eli Lilly has its way ... going from a major insulin provider to a GLP-1 injection juggernaut. Leading the charge is Patrik Jonsson, a 35-year Lilly veteran who got his start as a sales ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

Indianapolis-based drugmaker Eli Lilly and Company has announced ... by cutting the list price of its non-branded insulin, Insulin Lispro Injection 100 units/mL, to $25 a vial.

Eli Lilly’s big-selling insulin ... The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US ...

and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity.

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...